Intervention Increases Screening in Close Relatives of Colon Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

SAN DIEGO-First-degree relatives of colorectal cancer patients are at increased risk of getting the disease themselves, and it is generally recommended that they have colorectal cancer screening beginning at age 40. A new study suggests that educational interventions by phone and mail may increase screening rates in this high-risk population.

SAN DIEGO—First-degree relatives of colorectal cancer patients are at increased risk of getting the disease themselves, and it is generally recommended that they have colorectal cancer screening beginning at age 40. A new study suggests that educational interventions by phone and mail may increase screening rates in this high-risk population.

“Surprisingly, first-degree relatives of colon cancer patients often underestimate the risks, particularly lower-income patients and those whose affected relatives are older,” said Dennis J. Ahnen, MD, professor of gastroenterology, University of Colorado.

Dr. Ahnen presented results of an interventional study at an American Gastroenterological Association research forum held during the Digestive Disease Week conference.

“Our aim was to design, implement, and evaluate a brief, telephone-based educational and counseling intervention to promote cancer screening for this group,” he said.

Physicians from more than 30 hospitals across the United States gave permission for the researchers to contact their patients with colorectal cancer. After the patient gave informed consent, a telephone interview was conducted to obtain a list of eligible first-degree relatives—men and women 50 years and older who were English speaking, aware of the cancer diagnosis of the family member, and had no personal history of cancer.

Families with more than one eligible first-degree relative were randomized to intervention or control groups. Consenting first-degree relatives were sent an introductory letter, a brochure, and a core baseline computer-assisted telephone interview that measured colon cancer attitudes, beliefs, risk perceptions, and screening practices.

The intervention group, Dr. Ahnen said, also received a brief, tailored, motivational telephone barriers counseling module designed to encourage colorectal cancer screening, as well as a tailored, reinforcement mail-out. “We followed up with both groups after 3 and 12 months,” he said.

The researchers conducted 860 co-lorectal cancer patient interviews, which yielded 2,069 first-degree relatives. Of those, 1,266 completed the baseline interview (38% men and 62% women). So far, Dr. Ahnen reported, 969 first-degree relatives have completed the 3-month interview and 599 the 12-month interview.

The study population is predominately white (84%), well educated (67% with some college or more), and affluent (63% earn $40,000 a year or more).

At baseline, Dr. Ahnen said, 45% of the participants reported colorectal screening within the recommended guidelines (fecal occult blood tests within 1 year or endoscopic screening within the past 5 years). At the most recent analysis, the rate of adherence to the guidelines had increased to 72% in the intervention group and 57% in the control group.

“The preliminary results indicate that phone-based education and counseling can significantly improve screening rates in first-degree relatives of colorectal cancer patients,” Dr. Ahnen concluded.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content